Second quarter fiscal 2004 revenues for Hologic totaled $55.6 million, an 11% increase compared with revenues of $50.3 million in the second quarter of fiscal 2003. For the quarter ended March 27, 2004, the company reported net income of $2.6 million
Second quarter fiscal 2004 revenues for Hologic totaled $55.6 million, an 11% increase compared with revenues of $50.3 million in the second quarter of fiscal 2003. For the quarter ended March 27, 2004, the company reported net income of $2.6 million compared with net income of $344,000 in the year-earlier period. Company execs attributed the improvement in earnings to decreasing expenses associated with the company's planned reduction of its general radiography systems business and to increased revenues, which came largely from the continuing sales shift from film-based mammography products to the higher margin Selenia full-field digital mammography system.
During the current quarter, Hologic installed and recognized as revenue 35 Selenia systems, which drove a 40% increase in mammography revenues to $27.9 million. As of the end of the quarter, 74 of these units valued at $53 million were on back order. Digital detector sales contributed further, generating $3 million, up 34% from the year-earlier period. Revenues were down 10%, however, for equipment related to osteoporosis assessment, as company sales tallied just $16.5 million of this equipment compared with $18.5 million in 2Q 2004.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.